10-Q: Charlies Holdings Reports Q2 2024 Results Amidst Regulatory and Financial Challenges

Charlies Holdings experienced a significant revenue decline and net loss in Q2 2024, while navigating a complex regulatory landscape and ongoing concerns about its ability to continue as a going concern.

Summary

• Charlies Holdings reported a net loss of $967,000 for the three months ended June 30, 2024, compared to a net income of $32,000 for the same period in 2023.
• Revenue decreased by 48.5% to $2.043 million for the quarter, primarily due to lower sales of nicotine-based vapor products and hemp-derived products.
• For the six months ended June 30, 2024, the company's net loss was $2.012 million, compared to a net loss of $1.358 million for the same period in 2023.
• Six-month revenue declined by 36.3% to $5.094 million, with significant decreases in both nicotine-based and hemp-derived product sales.
• The company's working capital position worsened to a deficit of $557,000 as of June 30, 2024, compared to a working capital of $332,000 at the end of 2023.
• The company has ongoing concerns about its ability to continue as a going concern due to regulatory risks, low working capital, and cash position.
• The company has invested approximately $6 million in the PMTA process with the FDA.
• The company has implemented cost-cutting measures, including salary reductions and headcount reductions.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture with significant revenue declines, net losses, and a deteriorating working capital position. The company also faces substantial regulatory risks and uncertainty about its ability to continue as a going concern. While there are some positive developments, such as the launch of new products and a capital raise, the overall sentiment is negative due to the significant challenges and risks the company faces.

Positives

• The company launched SPREE BAR, a non-nicotine disposable vapor product, which is not subject to FDA review.
• The company completed a capital raise of approximately $1.63 million in May 2024.
• The company is developing a Metatine-based pouch line for potential launch in January 2025.
• The company is developing patented age-gating technology to prevent youth access to nicotine vapor products.
• The company has an international distribution platform and is focusing on growing its market share internationally.

Negatives

• The company experienced a significant decrease in revenue for both the three and six months ended June 30, 2024.
• The company reported a net loss for both the three and six months ended June 30, 2024.
• The company's working capital position has deteriorated to a deficit.
• The company faces substantial regulatory risks and uncertainty regarding FDA approvals.
• The company has a low cash position and is facing challenges in its ability to continue as a going concern.
• The company has experienced periodic stockouts of its e-liquid products.

Risks

• The company operates in a rapidly changing legal and regulatory environment, which could significantly limit its ability to sell its products.
• The company's products are subject to FDA approval, and there is no assurance that the FDA will approve previous or future applications.
• The company faces the risk of receiving Marketing Denial Orders (MDOs) from the FDA, which would require the removal of products from the market.
• The company's synthetic nicotine products are subject to the same FDA rules as tobacco-derived nicotine products.
• The company's new SPREE BAR products, while believed to be outside of FDA jurisdiction, could be subject to FDA regulation in the future.
• The company's ability to continue as a going concern is dependent on its ability to increase revenues and procure cost-effective financing.
• The company's ability to utilize its net operating losses (NOLs) and tax credit carryforwards may be limited by ownership changes.

Future Outlook

The company plans to continue developing new product formats, including Metatine-based products, and is seeking FDA marketing authorization for its nicotine and synthetic nicotine vapor products. The company also intends to grow its market share internationally and develop age-gating technology to prevent youth access to nicotine vapor products. The company may require additional financing in the future to support these initiatives.

Management Comments

• Management has targeted opportunities for growth and has adopted an operational plan to achieve competitive advantages in the vapor and alternative products marketplace.
• Management believes that the market for nicotine and alternative alkaloid products, such as SPREE BAR, offers the company the most significant opportunity for growth.
• Management is committed to continuous improvement of its alternative alkaloid products to satisfy adult consumer demands.
• Management believes that obtaining one or more marketing orders from the FDA could help to remediate perceived health issues related to vaping and further position the company as a trusted industry leader.
• Management has dedicated additional resources to efforts focused on growing its market share internationally.

Industry Context

The company operates in the highly regulated and competitive vapor products industry, facing challenges from changing laws and regulations, FDA scrutiny, and competition from both large tobacco companies and smaller players. The company's focus on alternative alkaloid products and age-gating technology reflects a broader industry trend towards innovation and addressing regulatory concerns.

Comparison to Industry Standards

• The company's revenue decline is significant compared to the overall growth seen in some segments of the vapor products market, particularly in the disposable vape category.
• The company's substantial investment in PMTA submissions, while common in the industry, has not yet yielded significant approvals, highlighting the challenges of navigating the FDA regulatory process.
• The company's development of age-gating technology aligns with efforts by larger competitors like JUUL, Altria, and R.J. Reynolds, indicating a focus on addressing regulatory concerns about youth access.
• The company's shift towards non-nicotine products with SPREE BAR is a strategic move to mitigate regulatory risks, similar to other companies exploring alternative nicotine delivery systems.
• The company's financial performance, particularly its net losses and working capital deficit, is concerning compared to industry benchmarks for companies with similar revenue levels.

Related Party Transactions

• The company leases office space from entities controlled by Brandon and Ryan Stump.
• The company issued unsecured promissory notes to several of its executives and employees, and to three of its largest stockholders.
• The company entered into a loan agreement with its Chief Operating Officer and Director, Ryan Stump.

Stakeholder Impact

• Shareholders face the risk of losing some or all of their investment due to the company's financial challenges and regulatory risks.
• Employees have experienced salary reductions and headcount reductions as part of cost-cutting measures.
• Customers may be affected by potential product removals due to FDA regulations.
• Suppliers may be impacted by the company's financial difficulties and potential changes in purchasing patterns.
• Creditors face the risk of non-payment due to the company's financial challenges.

Next Steps

• The company plans to continue developing new product formats, including Metatine-based products.
• The company is seeking FDA marketing authorization for its nicotine and synthetic nicotine vapor products.
• The company intends to grow its market share internationally.
• The company is developing age-gating technology to prevent youth access to nicotine vapor products.
• The company may require additional financing in the future to support these initiatives.

Key Dates

Keywords

nicotine, vapor products, FDA, PMTA, Metatine, SPREE BAR, regulatory, financial results, going concern, hemp-derived products, capital raise